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Hydroxyurea and its derivatives exhibit versatile biological activities. Hydroxyurea
is currently used in the treatment of various neoplastic and non-neoplastic diseases such
as cancer, sickle cell anemia and HIV (1). Derivatives of hydroxyurea were found to inhi-
bit matrix zinc metaloproteinases (MMP), urease, carboanhydrase, carboxypeptidase,
cyclooxygenase and 5-lipooxygenase. Early experiments on antibacterial properties and
effects on tumor cell lines of hydroxyurea and low molecular mass derivatives were in-
vestigated in the 1960s (2–3). Recently, hydroxyurea was recognized as a leading com-
pound in nitric oxide donor synthesis (4).
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Synthesis and biological evaluation of a series (N = 16) of
cyclic and acyclic hydroxyurea derivatives, including ben-
zotriazole-, isocyanuric acid- and biuret-containing com-
pounds, are disclosed. 1-N-(benzyloxycarbamoyl)benzo-
triazole was used as a benzyloxyisocyanate donor, a useful
intermediate in the preparation of substituted hydroxy-
urea. Antibacterial activities of synthesized hydroxyurea
derivatives were tested on three E. coli strains, i.e., a strain
susceptible to antibiotics, a strain resistant to macrolide
antibiotics and a strain resistant to aminoglycoside anti-
biotics. Six compounds (three acyclic and three cyclic hy-
droxyureas) showed growth inhibition of the tested E. coli
strains, with different specificity toward each strain. Re-
sults of the cytotoxic activity evaluation revealed that
twelve out of sixteen test compounds were cytotoxic to
human acute monocytic leukemia THP-1 and/or human
acute T cell leukemia Jurkat cell line. 1-(N-hydroxycarba-
moyl)benzotriazole (5) increased the metabolic activity of
both cell lines. Two compounds, 1-(N-hydroxycarbamo-
yl)benzotriazole (5) and N,N’,N’’-trihydroxybiuret (15),
were identified as potential NO donors.
Keywords: hydroxyurea derivatives, synthesis, antibacte-
rial activity, cytotoxicity
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Continuing our studies on physical, chemical and biological properties of hydroxu-
rea derivatives (5–8), we report here the synthesis of a series of hydroxyurea derivatives
along with their effects on metabolic activity on two human cell lines (human acute mo-
nocytic leukemia suspension cell line THP-1, and human acute T cell leukemia suspen-
sion cell line Jurkat) and their antibacterial activity against three E. coli strains.
EXPERIMENTAL
Materials and methods
Melting points were measured on a Stuart SMP3 Melting Point Apparatus (Barlo-
world Scientific Ltd., UK). NMR spectra were recorded on a Varian Gemini 300 (Varian,
USA) spectrometer at 300 MHz for 1H and 75 MHz for 13C nucleus. Samples were mea-
sured in DMSO-d6 solution in 5-mm NMR tubes. Chemical shifts, d, are given in ppm
and referenced to tetramethylsilane (TMS). IR-spectra were recorded on a FT-IR Perkin
Elmer Paragon 500 spectrometer (PerkinElmer, USA) for samples dispersed in KBr pel-
lets. Elemental analysis was performed on a CHNS LECO-932 Analyzer (LECO Corpo-
ration, USA); the obtained results are within ± 0.4 % of theoretical values. UV-VIS spec-
tra were recorded on a Varian Cary 50 spectrophotometer (Varian, USA).
Benzotriazole, tetrahydrofurane, O-ethylhydroxylamine hydrochloride, urea, L-so-
dium ascorbate, and triethylamine (TEA) were purchased from Fluka (Germany). Triphos-
gene, O-methylhydroxylamine hydrochloride, O-benzylhydroxylamine hydrochloride,
4-aminobenzoic acid, imidazole, and hydrochloric acid were purchased from Sigma-
-Aldrich (USA), while acetone, toluene, methanol, and diethyl ether were from Kemika
(Croatia). Dioxane was from Riedel-de Haën (Germany). Dimethyl sulfoxide (DMSO) was
purchased from Merck (Germany). Mn(III)-5,10,15,20-tetrakis(N-ethylpyridinium-2-yl)
porphyrin (MnTE-2-PyP5+) was prepared by a previously published procedure (9).
Phosphate-buffered saline (PBS) was from Gibco (USA). LB medium (Luria-Bertani me-
dium) was from Becton Dickinson (UK). RPMI 1640 medium was from Invitrogen (USA).
Doubly distilled argon purged CO2-free water was used. All stock solutions of tested
compounds in E. coli and cell viability experiments were freshly prepared before use by
dissolving an appropriate amount in DMSO to a final concentration of 0.5 mol L–1.
Cell lines. – THP-1 cell line (TIB-202™) and Jurkat cell line (TIB-152™) were obtain-
ed from the American Type Culture Collection (USA). All experiments were performed
on cells between passages 5 and 10. After 15 passages, cells were discarded and replaced
by frozen stocks.
Bacterial cultures. – Escherichia coli DH5a, BL21(DE3) and the expression vector pET-
-25b(+) were obtained from Novagen (USA), pUC18 vector was from GE Healthcare Life
Sciences (USA). E. coli DH5a (supE44 DlacU169(Q80lacZDM15) hsdR17 recA1 endA1
gyrA96 thi-1 relA1) – a strain with natural sensitivity to antibiotics, DH5a/pUC18-ermC’ –
a strain DH5a carrying a gene for methyltransferase ErmC’, which renders E. coli resistant
to erythromycin and other macrolide antibiotics (10), and BL21(DE3)/pET25b(+)-sgm (F-
ompT hsdSB(rB-mB-)gal dcm (DE3) – an expression strain of E. coli containing a gene for
methyltransferase Sgm, which makes E. coli resistant to kanamycin and other 4,6-deoxy-
streptamine aminoglycosides were used (11).
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Measurement of bacterial growth in microtiter plates – microdilution assay. – Serial dilu-
tions of test compounds were prepared by dilution of stock solutions, either with LB me-
dium (for E. coli strain DH5a) or with LB medium supplemented with 100 mg L–1 of
ampicillin (for E. coli strains DH5a/pUC18-ermC’ and BL21(DE3)/pET25b(+)-sgm). The
total volume in each well was 200 mL and final concentrations of test compounds in the
wells, after the addition of all components, were 0.001, 0.01, 0.1 and 1 mol L–1. The over-
night bacterial culture was diluted in fresh LB medium (1:50) (E. coli DH5a) or in LB me-
dium supplemented with 100 mg L–1 of ampicillin (E. coli DH5a/pUC18-ermC’ and E.
coli BL21(DE3)/pET25b(+)-sgm) and grown until OD600 was 0.8–1. Cultures were diluted
to approximately 5 × 105 cells mL–1 and an aliquot of 100 µL of the suspension was ad-
ded to the wells containing serial dilutions of test compounds. Additional wells which
contained only the corresponding dilutions of test compounds in growth medium, were
used as controls for compounds that were either colored or showed some absorbance in
the absence of bacteria. Each microtiter plate contained a control of sterility (200 µL of
LB medium), bacterial growth control (100 µL of LB medium, for E. coli strain DH5a, or
LB medium with ampicillin, for E. coli strains DH5a/pUC18-ermC’ and BL21(DE3)/
pET25b(+)-sgm) and 100 µL of bacterial inoculum), and a control of compound sterility
(150 µL of LB medium and 50 µL of highest concentration of test compound). Microtiter
plates were incubated for 18 h at 37 °C and bacterial growth was measured at 570 nm us-
ing a microplate reader Biohit BP 800 (Biohit, Finland).
Metabolic MTS assay. – Metabolic activity and the potential cytotoxic effect of test
compounds were investigated using the CellTiter 96®AQueous One Solution Cell Prolif-
eration Assay (Promega, USA). Fifty µL of the cell culture (2 × 105 cells mL–1, i.e., 104
cells per well) or fifty µL of RPMI 1640 medium were transferred into the wells of a
96-microwell plate. Test compounds were initially dissolved in DMSO, serially diluted
in culture medium and 50 mL of 2-fold dilution was added into each well to obtain the fi-
nal concentration of 0.001, 0.01, 0.1 and 1 mmol L–1. Controls contained the test model
cells and culture medium (containing the same final concentration of DMSO, < 0.2 %),
but no test compounds. A negative control (medium without cells but with test com-
pounds) was used as a blank. Cells were incubated for 24, 48 and 72 hours before addition
of 20 mL 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-te-
trazolium (MTS) and were additionally incubated in the dark at 37 °C for the following 2
hours. The absorbance was measured at a wavelength of 490 nm using a microplate rea-
der Victor2-1420 Multilabel Counter (PerkinElmer). Two series of experiments were per-
formed in triplicates. Data were analyzed by the one-way analysis of variance (ANOVA).
Because of accuracy of the method any difference was considered significant if larger
than ± 20 % and at p < 0.05.
Manganese porphyrin test. – Spectrometric assay for nitric oxide was performed by
modification of a previously published procedure (12). A 1 mmol L–1 manganese(III)-
5,10,15,20-tetrakis(N-ethylpyridinium-2-yl) porphyrin (MnTE-2-PyP5+) with 1 mmol L–1
sodium L-ascorbate in PBS, pH 7.4 was prepared. Stock solutions of tested compounds
were prepared by weighing an appropriate amount of compound and dissolving it in
distilled water to a final concentration of 1 mmol L–1. PBS solution (1 mL) was mixed
with 1 mL of a freshly prepared solution of the tested compound. Spectra were measur-
ed in an airtight 1-cm quartz cuvette cell in a range of 350 to 600 nm.
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Syntheses
1,1-Carbonylbisbenzotriazole (1,1-carbonylbis(1H-1,2,3-benzotriazole) (1). – It was synthesized
by modification of a previously published procedure of Katritzky and coworkers (13),
where a phosgene solution (20 % in toluene) was replaced with a solid triphosgene. Com-
pound 1 was prepared by mixing 2.30 g (0.02 mol) of 1-H-benzotriazole with 1.19 g (0.004
mol) of triphosgene in dry tetrahydrofurane for 72 h. THF was evaporated and the solid
product was suspended in water. The suspension was acidified with HCl (1:1) up to pH 3
and mixed for 3 hours. The solid product was filtered off and dried in vacuo over P2O5.
Benzotriazole N-carbamoyl derivatives (2, 3 and 4). – N-carbamoyl derivatives of ben-
zotriazole were synthesized in the reaction of 1 with the corresponding hydroxylamine
derivative in dioxane solution at room temperature (Scheme 1). Compound 1 (2.68 g,
0.01 mol), 0.01 mol of the corresponding hydroxylamine (1.60, 0.83 and 0.97 g of benzyl-
oxyamine hydochloride, methoxyamine hydrochloride, and ethoxyamine hydoxychlo-
ride, respectively) and 1.1 g (0.01 mol) TEA were dissolved in 50 mL of dry dioxane. The
solution was vigorously mixed for 48 h at room temperature. TEA´HCl was filtered off
and washed with 10 mL of dioxane. The filtrate was evaporated to the consistency of oil
and crystallized from water. The obtained product was filtered off, washed with HCl
(pH 3), water and dried for 24 h in air and in vacuo over P2O5 at room temperature.
N-benzyloxybiuret (6). – Compound 2 (2.68 g, 0.01 mol), 0.60 g (0.01 mol) of urea and
0.34 g (0.005 mol) of imidazole were heated at 130 °C for 10 minutes. After cooling to
room temeperature, the solid mixture was suspended in water and acidified with HCl to
pH 3. The product was filtered off, washed with water and dried over P2O5.
4-(Benzyloxycabamoyl)aminobenzoic acid (7). – Compound 2 (2.68 g, 0.01 mol), 1.37 g
(0.01 mol) of 4-aminobenzoic acid and 0.68 g (0.01 mol) of imidazole were mixed at 130 °C
for 15 minutes. The cooled mixture was suspended in water and acidified with HCl to
pH 3. The white product was filtered off, washed with water, recrystallized from ethanol
and dried in vacuo over P2O5.
N,N’-bisbenzyloxyurea (9). – Compound 2 (2.68 g, 0.01 mol), 1.60 g (0.01 mol) benzyl-
oxyamine hydrochloride and 1.01 g (0.01 mol) TEA were suspended in 50 mL of dry
dioxane. The reaction mixture was mixed for 48 hours at room temperature. TEA×HCl
was filtered off and washed with 10 mL of dry dioxane. The solvent was removed and
the obtained oil was crystallized with the addition of water. The white solid product was
washed with HCl (pH 3) and water, recrystallized from ethyl acetate and hexane and
dried over P2O5 in vacuo.
1-(N-hydroxycarbamoyl)benzotriazole (5), N-hydroxybiuret (12),
4-(hydroxyaminocarbonyl)aminobenzoic acid (13), N-hydroxyurea (14),
N,N’,N’’-trihydroxyisocyanuric acid (16) and N,N’,N’’-trihydroxibiuret (15)
A mixture of 1-(N-benzyloxycarbamoyl)benzotriazole (2), N-benzyloxybiuret (6),
4-(benzyloxycabamoyl)aminobenzoic acid (7), N-benzyloxyurea (8), N,N’,N’’-tribenzyl-
oxyisocyanuric acid (10) or N,N’,N’’-tribenzyloxybiuret (11) and 0.05 g palladium on car-
bon (Pd/C, 10%) in methanol (100 mL) was kept under hydrogen (r. t., normal pressure)
for 1–10 hours. Pd/C was filtered off and methanol was evaporated. The obtained prod-
ucts 5, 12, 13, 14, 16 and 15, respectively, were dried over P2O5 in vacuum and were ob-
tained in practically theoretical yields.
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N-benzyloxyurea (8), N,N’,N’’-trihydroxyisocyanuric acid (16) and its triacetyl ester (17)
were prepared according to previously published procedures (6, 14, 15).
RESULTS AND DISCUSSION
Chemistry
A reported synthesis of 1-(N-benzyloxycarbamoyl)benzotriazole (2) included the reac-
tion of 1-(N-carbamoylchloride)benzotriazole with benzyloxyamine hydrochloride (15).
In our research, 1,1’-carbonylbisbenzotriazole (1) was used in reactions with the corres-
ponding oxyamine hydrochlorides (benzyloxyhydroxylamine hydrochloride, methoxy-
amine hydrochloride and ethoxyamine hydrochloride) and triethylamine in dioxane
suspension. Compound 1 was prepared in a suspension of 1-H-benzotriazole and a solid
triphosgene instead of phosgene in toluene (20 % solution), which is less aggressive, more
stable and ecologically more friendly. The use of 1 in reactions with methoxy-, ethoxy-
and benzyloxy-amines afforded 2, 1-(N-metoxycarbamoyl)benzotriazole (3) and 1-(N-
ethoxycarbamoyl)benzotriazole (4) with yields of 87, 76 and 82 %, respectively (Scheme
1). Among them, only 2 reacted with hydrogen in the presence of palladium/carbon (Pd/C,
10 %), which resulted in 1-(N-hydroxycarbamoyl)benzotriazole (5) in quantitative yield.
Uesato et al. (16) reported the use of benzyloxyisocyanate as a useful building block in
the synthesis of hydroxyurea derivatives, while Butula and Jadrijevi}-Mladar Taka~ (14)
reported that 2, when heated over 100 °C liberates benzyloxyisocyanate which is further
trimerized to N,N’,N’’-tribenzyloxy-triazinone (10), and yields a minor product N,N’,N’’-
-tribenzyloxybiuret (11). In this work, we utilized 2 as a donor of benzyloxyisocyanate,
which is very useful for the synthesis of hydroxyurea derivatives. Due to its low solubil-
ity in water, 2 and products of its reactions can be easily separated from all water soluble
substances and reaction products. When heated up to 130 °C in reactions with urea or
4-aminobenzoic acid, in the presence of imidazole as a catalyst, it afforded N-benzyloxy-
biuret (6) and 4-{[(benzyloxy)carbamoyl]amino}benzoic acid (7) with yields of 68 and 81
%, respectively. Under the same experimental conditions, 1 in the reaction with N-ben-
zyloxyurea (8) and N,N’-bisbenzyloxyurea (9) (17) did not yield the expected di- and
trisubstitued biurets (18). Instead, trimerization occurred and only compound 10 was
isolated from the reaction mixture.
Compounds 2, 6, 7, 8, 10 and 11 were hydrogenated with hydrogen under atmo-
spheric pressure at room temperature, in the presence of a catalytic amount of palla-
dium on carbon (Pd/C, 10 %) (14). The corresponding hydroxyl derivatives, i.e., 1-(N-
hydroxycarbamoyl)benzotriazole (5), N-hydroxybiuret (12) (20), 4-{[(hidroxy)carba -
moyl]amino}benzoic acid (13), N-hydroxurea (14), N,N’,N’’-trihydroxybiuret (15) (20)
and N,N’,N’’-trihydroxyisocyanuric acid (16) were obtained in quantitative yields. The
synthetic routes and structures of isolated compounds are presented in Scheme 1,
whereas their physicochemical data are summarized in Tables I and II.
The synthesized set of compounds (Table I) represents different derivatives of hy-
droxyurea, which can be categorized into several subgroups, i.e., benzotriazole N-carba-
moyl derivatives (2, 3, 4 and 5), cyclic- (10, 16 and 17) and acyclic hydroxyurea derivati-
ves (7, 8, 9, 13 and 14), and biuret derivatives (6, 11, 12 and 15).
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3246, 3113, 3030, 2947, 2884,
1728, 1603, 1484, 1367, 1289,
1231, 1132, 1093, 1003, 924,
869, 751, 699, 563
9.95 (s, 1H, NH), 8.20 (d, 3JH,H
= 8.2 Hz, 1H), 8.09 (d, 3JH,H =
8.5 Hz, 1H), 7.67 (t, 3JH,H = 7.7
Hz, 2H), 7.48 (t, 3JH,H = 7.7 Hz,
3H), 7.34 (d, 3JH,H = 4.4 Hz,






3310, 1730, 1492, 1474, 1448,
1320, 1378, 1292, 1234, 1162,
1134, 1092, 1018, 934, 924,
856, 748, 772, 756, 548
9.96 (s, 1H, NH), 8.25 (d, 3JH,H
= 8.3 Hz, 1H), 8.1 (d, 3JH,H = 8.1
Hz, 1H) 7.5 (t, 3JH,H = 7.6 Hz,
1H), 7.48 (t, 3JH,H = 7.5 Hz, 1H),





3280, 2982, 1756, 1592, 1494,
1450, 1382, 1286, 1298, 1230,
1138, 1022, 960, 926, 876, 854,
816, 780, 774, 758, 538, 512, 490
9.85 (s, 1H, NH), 8.20 (d, 3JH,H
= 8.1 Hz, 1H), 8.15 (d, 3JH,H =
8.3 Hz, 1H) 7.2 (t, 3JH,H = 7.7
Hz, 1H), 7.55 (t, 3JH,H = 7.7 Hz,
1H), 4.04 (q, 3JH,H = 7.0 Hz, 2H,
CH2), 1.26 (t,







3297, 3132, 2939, 2876, 1750,
1711, 1610, 1536, 1489, 1451,
1368, 1290, 1240, 1135, 1104,
1017, 936, 870, 785, 744, 644
8.86 (s, 1H, OH), 8.37 (s, 1H,
NH), 7.92 (s, 2H, H4 and H7),




3360, 3236, 1690, 1682, 1582,
1606, 1496, 1456, 1390, 1366,
1286, 1244, 1132, 1092, 1042,
970, 928, 908, 788, 744, 698,
648, 626, 594, 518, 480, 462
10.09 (s, 1H, NH-O), 8.66 (s,
2H, CONHCO), 7.40 (m, 5H,






3284, 3030, 2676, 2560, 1700,
1676, 1658, 1606, 1552, 1498,
1430, 1324, 1294, 1236, 1178,
1108, 1042, 1002, 926, 916, 876,
860, 788, 764, 748, 728, 696, 668,
668, 638, 610, 552, 504, 427
12.64 (s, 1H, COOH), 9.69 (s,
1H, NH-O-), 9.08 (s, 1H, NH),







3398, 3224, 1680, 1630, 1456,
1418, 1358, 1210, 1106, 1058,
998, 940, 906, 798, 748, 696,
644, 622, 588, 560, 494
9.05 (s, 1 H, NH), 7.39 (m, 5H,





3230, 3064, 3030, 2924, 1668,
1466, 1454, 1356, 1306, 1208,
1116, 1072, 1016, 986, 934, 908,
840, 810, 738, 696, 668, 626, 580,
544, 490
9.86 (s, 2H, NH), 7.37 (m, 10H,
ar.H), 4.73 (s, 4H, CH2)
159.39, 136.10, 128.60,
128.03, 127.89, 77.19
IR spectra of benzotriazole N-carbamoyl derivatives 2 to 5 are characterized with
C=O stretching vibrations in the range nC=O from 1728 to 1756 cm–1. These vibrations are
shifted towards higher frequency values compared to urea stretching vibrations due to
dipole characteristics of carbamoyl moiety. The NH stretching vibrations of 2 to 5 were
observed in the range nNH 3248 to 3310 cm–1, while in the spectrum of 5 the NHOH
stretching vibrations were revealed from n 3554 to 2500 cm–1 as strong broadbands.
1H NMR spectra of 2 to 5 showed chemical shifts for benzotriazole ring protons in
the range from d 7.00 to 8.50 ppm with two characteristic signals, one doublet and one
triplet, in addition to benzyl protons in the spectrum of 2 and methyl and ethyl protons
in the spectra of 3 and 4, respectively. Chemical shifts, d OH and d NH in 5 were observ-
ed as two separated signals, at 8.86 and 8.37 ppm.
13C NMR spectra of 2 to 5 showed chemical shifts for the C=O group at d 148.68,
148.76, 148.87 and 162.68 ppm, respectively.
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10
(15)
3034, 2956, 2924, 1740, 1457,
1402, 1197, 1001, 905, 750,
696, 476
7.56 (d, 2H, 2JH,H = 4.7 Hz, H3’
and H7’), 7.46 (t, 3H, 3JH,H = 4.9





3287, 3064, 3032, 2943, 2888,
1716, 1566, 1364, 1298, 1215,
1189, 1028, 965, 904, 839,
738, 750, 700, 610, 543, 501
10.92 (s, 2H, NH), 7.39 (m,






3440, 3394, 3328, 3220, 3126,
2876, 1716, 1676, 1578, 1522,
1412, 1328, 118,1052, 890,
794, 762, 720, 690, 668, 618,
538, 468
9.49 (s, 1H, OH), 9.08 (s, 1H,
CONH-O), 8.31 (s, 1H,
CONHCO), 6.98 (s, 2 H, NH2)
156.73, 154.04
13
3352, 3232, 2896, 2660, 2548,
1686, 1652, 1542, 1520, 1420,
1294, 1320, 1234, 1184, 1126,
1092, 998, 940, 882, 862, 840,
772, 720, 696, 658, 638, 596,
556, 510
12.59 (s, 1H, COOH), 9.20 (s,
1H, NOH), 9.05 (s, 2H, NH),




3318, 3208, 2818, 1652, 1594,
1490, 1408, 1112, 824, 764,
626, 560
8.66 (s, 1H, OH), 8.34 (s, 1H,
NH), 6.25 (s, 1H, N’H)
162.52
15
3362, 3282, 3204, 1718, 1664,
1552, 1504, 1316, 1180, 1056,
892, 802, 688, 560, 468
10.21 (s, 2H, 2OH), 10.13 (s,




3535, 3427, 2916, 2849, 2706,
1720, 1568,1434,1212, 1164,
1010, 702, 478
11.11 (s, 3H) 147.19
17
(7)
1829, 1749, 1403, 1369, 1213,
1146, 1015, 824, 804, 788,
730, 585
1.91 (s, 9H) 174.81, 143.54, 24.21
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IR spectra of cyclic hydroxyurea derivatives (10, 16 and 17) revealed three very strong,
almost overlapped, stretching vibrations for cyclic C=O in the range from 1674–1745 cm–1
(nmax 1740 cm–1) for 10, 1648–1720 cm–1 for 16 (nmax 1718 cm–1) and 1750–1714 cm–1 for
17 (nmax 1749 cm–1). In addition, in the spectrum of 17 the nC=O of three ester moieties
were found as a single stretching vibration at 1829 cm–1.
Due to high symmetry and equivalence of functional moieties in the molecules of
cyclic hydroxyurea derivatives (10, 16 and 17), the 1H and 13C NMR spectra of these
compounds are very simple. In 1H NMR spectra, the following chemical shifts were re-
vealed at d 7.56–7.46 (Har.) and 5.13 ppm (benzyl -CH2-) in 10, only one signal for proton
in OH in 16 at d 11.11 ppm, and only one signal for CH3 protons in 17 at d 1.91. In 13C
NMR spectra of 10, 16 and 17, chemical shifts of C-atoms in the corresponding carbonyl
groups involved in triazintrione ring systems were found at 145.37, 147.19 and 143.54
ppm, respectively. The downfield of chemical shifts for C-atom in C=O of the
triazintrione ring was observed in the order 16 > 10 > 17 due to the chemical type of
compound and involved substituents (OH, benzyl and acetyl). The chemical shift of es-
ter carbonyl group in the spectrum of 17 was observed more downfield at d 174.81 ppm.
Compared to stretching vibrations of C=O groups immersed in the triazintrione ring
system of cyclic urea derivatives, analogous nC=O, in hydroxyurea and its acyclic deriva-
tives (7, 8, 9, 13 and 11) were observed as a very strong and single stretching vibration at
lower frequencies, i.e., at n 1658, 1680, 1668, 1686 and 1652 cm–1, respectively. The 1H
NMR spectra of compounds 7, 8, 9, 11 and 13, showed typical chemical shifts that corre-
spond to protons in aromatic moieties (7, 8, 9 and 13), the carboxylic group (7 and 13),
and to NH and OH protons in hydroxyurea moieties in 13 and 14. Chemical shifts of hy-
droxyurea NH protons were observed in the range 6.24 to 9.86 ppm while chemical
shifts of hydroxyl protons (NH-OH) in the spectra of 13 and 14 were found at d 9.20 and
8.66 ppm, respectively. Comparing these chemical shifts with analogous proton chemical
shifts in the spectrum of 16, dN-OH in 1H NMR spectra of 13 and 14 were observed in a
higher field. The corresponding chemical shifts, dC=O, of hydroxyurea moieties of these
compounds were found at d 156.91 (7), 160.91 (8), 159.39 (9), 167.997 (13) and 162.51 (14)
ppm, and lower in the field compared to dC=O of triazintrione moieties in 10, 16 and 17
by more than 10 ppm (d range 13 to 15 ppm) These differences in chemical shifts can be
attributed to the strained triazintrione ring with cyclic poly-hydroxyurea moieties.
The basic structure of all synthesized biuret derivatives (6, 11, 12 and 15) is
R1(NH)CON(R2)CON(R3). The IR spectra of these compounds in the part of functional
groups are characterized by one strong stretching vibration for both C=O groups in each
spectrum of 6 and 11 (n 1682 and 1716 cm–1, respectively), hydroxyl biuret group is mask-
ed by benzyl moiety, while in 12 and 15 the OH group is free, and two very strong vibra-
tions for C=O were observed at n 1716 and 1676 cm–1 in the spectrum of 12, and at 1718
and 1664 cm–1 in the spectrum of 15. Additionally, in the spectra of 12 and 15, in part of
OH, NH2 and NH stretching vibrations, several broadband vibrations were overlapped
in the range from 3340 to 3000 cm–1, while in the spectra of 6 and 11, only two sharp vi-
brations in each spectrum were observed, i.e., at n 3360 and 3236 cm–1 in 6 and at 3350
and 3288 cm–1 in 11.
The 1H NMR spectra of biuret derivatives 6 and 11 were represented by NH2 and
NH in the range from 8.66 to 10.98 ppm, d of Har in the range from 7.05 to 7.40 ppm,
while d of CH2 benzyl protons were observed in the range from 4.80 to 4.88 ppm. Proton
184
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NMR spectra of 12 and 15 consisted only of chemical shifts for OH, NH2 and NH pro-
tons, which were observed in the range from 8.66 to 10.09 ppm. In the molecule 11 only
one signal was observed for both NH protons, while in 15 three signals were observed at
d 10.21 ppm for two –NH-OH, 10.13 ppm for N-OH and 8.927 ppm for both NH protons.
In 13C NMR spectra of compounds 11 and 15, only one signal for both C=O groups was re-
vealed at d 153.02 and 155.41 ppm, in each spectrum, while in asymmetrically substi-
tuted biuret compounds 6 and 12, two chemical shifts were observed for each C=O in
each spectrum, i.e., 154.10 and 155.47 (6), and d 154.04 ppm and 156.73 ppm (12).
Metabolic activity
To date, there is no data on the cytotoxic effects of synthesized compounds 2–17 on
human acute monocytic leukemia THP-1 and human acute T cell leukemia Jurkat cell
line, so we investigated the effects of compounds in the 0.001, 0.01, 0.1 and 1 mmol L–1
concentrations of the compounds on the metabolic status of the cells using the MTS as-
say.
The results of this study showed that compounds 6, 8 and 10 were not cytotoxic up
to 1 mmol L–1 to either leukemia cell line tested, nor changed the metabolic status of the
cells. Only compounds 7, 14 and 15 influenced the metabolic status of the cells at con-
centrations lower than 1 mmol L–1 in a manner described below: the toxic effect (~50 %)
of 0.1 mmol L–1 of the compound 13 was observed only on THP-1 cells, while com-
pound 15 showed a stimulative effect at 0.1 mmol L–1 concentration on both cell lines, and
increased metabolic activity of THP-1 cell line by 45 % and Jurkat cell line by 39 % (data
not shown). Compound 7 decreased the metabolic activity of Jurkat cells by ~34, 31 and
66 % in respect to control cells, when applied at 0.01, 0.1 (data not shown) and 1 mmol
L–1 concentrations (Fig. 1b), respectively. Such effect was not observed on THP-1 cells;
just a slight decrease of metabolic activity was detected at 1 mmol L–1 (Fig. 1a).
Among sixteen investigated compounds, eleven compounds showed a significant
effect on the metabolic status of the cells at a concentration of 1 mmol L–1 (Figure 1). Ten
compounds were toxic either to both or at least to one type of cells, while compound 5
showed a stimulative effect (of ~55 % on THP-1 cells and ~25 % on the Jurkat cell line).
An extensive (more than 70 %) toxic effect on both cell lines was detected at 1 mmol L–1
for compounds 9, 11, 12, 14 and 15. Compound 16 decreased the metabolic activity by
~54 % of the Jurkat cell line, while its acetyl derivative, 17, reduced the metabolic activity
of THP-1 by 34 % and of Jurkat cell lines by 43 %. Compounds 2, 3 and 4 showed a de-
crease in metabolic activity only for THP-1 cells, by 43, 35 and 39 %, respectively.
The cytotoxic effect of N-hydroxyurea 14 is well known and is based on its ability to
inhibit the M2 subunit of ribonucleotide reductase by quenching the tyrosine radical (21).
Gale et al. (22) reported a cytotoxic effect of N-hydroxybiuret, 12. In this study, both com-
pounds, 12 and 14, showed a strong cytotoxic effect on THP-1 and Jurkat cells, while
their corresponding benzyloxy derivatives (6 and 8) showed no activity, presumably be-
cause of the blocked OH group and consequently inability to quench the tyrosine radi-
cal. On the other hand, structurally similar derivatives, N,N’-bisbenzyloxyurea (9), and
N,N’,N’’-tribenzyloxybiuret (11), were highly toxic, compared to their hydroxy derivatives
6 and 7, which could imply another mode of action for these compounds. N,N’,N’’-trihy-
droxybiuret (15) showed a dose-dependent, opposing effect, being cytotoxic at 1 mmol
185
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Fig. 1. Effect of compounds 2-17 on the metabolic activity of THP-1 and Jurkat cells. a) THP-1 and
b) Jurkat cells were cultivated in the presence of 1 mmol L–1 compounds 2–17. Experiments per-
formed in triplicate are presented as percentage of metabolic activity of treated vs. untreated cells
(corrected for the corresponding media) ± SEM, n = 3. Changes in the metabolic activity of at least
20 % and p < 0.05 are marked with an asterisk.
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L–1 but stimulative at 0.1 mmol L–1 on both cell lines. The N’-benzyloxyurea derivative
of 4-amino benzoic acid, 7, decreased the metabolic activity of the Jurkat cell line at
1 mmol L–1 by 66 %, while its corresponding N’-hydroxyurea derivative, 13, decreased
the metabolic activity of both THP-1 and Jurkat cell lines at 1 mmol L–1 by 23 and 42 %,
respectively. In addition, compound 7 was toxic at 0.01 and 0.1 mmol L–1 on Jurkat cells.
These results suggest that compounds 7 and 13 decrease cell metabolic activity regard-
less of the hydroxylamine OH moiety being unprotected or derivatized with a benzyl-
oxy moiety. Compounds 2–5, which belong to a subgroup of benzotriazole analogues,
can be considered as reactive ureas. Unlike the insignificant toxic effect of compounds 2,
3 and 4 on Jurkat cell lines at 1 mmol L–1 (19, 4 and 5 %, respectively) and the slight toxic
activity on monocytic THP-1 cells at 1 mmol L–1 (34, 35 and 39 %, respectively), com-
pound 5, which is characterized by unprotected OH moiety, showed a stimulative meta-
bolic effect on both cell lines (61 % for THP-1 and 24 % for Jurkat). Different effects were
also reveled among isocyanuric acid derivatives 10, 16 and 17. The N,N’,N’’-tribenzyl-
isocyanuric acid (10) did not show any effect on either cell line, N,N’’,N’’-trihydroxyiso-
cyanuric acid (16) was toxic only to the Jurkat cell line (1 mmol L–1, 54 %), while its more
lipophylic triacetic acid ester derivative, 17, was toxic to both cell lines at 1 mmol L–1
concentration with a decrease of metabolic activity by 34 % for THP and 43 % for the
Jurkat cell line.
Antibacterial activity
The activity of compounds 2–17 was tested on three different E. coli strains at con-
centrations of 0.001, 0.01, 0.1 and 1 mmol L–1. Several compounds showed a significant
activity (defined as at least 20 % of decrease in bacterial growth) at concentrations of
1 mmol L–1 and the results are shown in Figure 2. No activity was observed at lower
concentrations. The most efficient compounds were 5, 10 and 15. They decreased the
bacterial growth of E. coli DH5a from 63 to 96 %, respectively, of E. coli strain
DH5a/pUC18-ermC’ from 60 to 86 %, and of strain BL21(DE3)/pET25b(+)-sgm from 50
to 93 %, respectively.
Among the investigated compounds, 10, 16 and 17, showed antibacterial activity.
They probably have similar mechanisms of action, though yet unknown, since they are
structural analogues. The activity of the two structurally different compounds (5 with a
benzotriazole ring and 15 as a biuret derivative) could not be assigned to a similar mecha-
nism like in the case of N,N’,N’’-trihydroxyisocyanuric acid analogues, hence some other
modes of action had to be considered. It is interesting, however, that compounds 5, 7
and 15 showed less evident antibacterial activity, either on the strain resistant to macrolide
antibiotics or on the sensitive DH5a strain, while 10, 16 and 17 showed stronger antibacte-
rial activity on the strain resistant to aminoglycoside antibiotics. Aminoglycoside resis-
tant strain expressed 16S rRNA methyltransferase Sgm, a member of the Arm family of
enzymes that methylate the N7 position of residue G1405 within the decoding- or A-site
in the small ribosomal subunit (23). This modification prevents 4,6-disubstituted
2-deoxystreptamine aminoglycosides from binding to the A-site, thus rendering them bac-
teria resistant (12).
The additional methyl group changes the form and depth of the aminoglycoside
binding pocket, but this rearrangement could simultaneously enable binding of different
187
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Fig. 2. The relative bacterial growth of E. coli strains DH5a, DH5a/pUC18-ermC’ and BL21(DE3)/
pET25b(+)-sgm in the presence of compounds 2–17 at concentration of 1 mmol L–1 represented as
the percentage of growth obtained for a control sample (bacterial strains grown in the absence of
tested compounds) ± SEM, n = 3.
Fig. 3. Spectra Mn(II)-5,10,15,20-tetrakis(N-ethylpyridinium-2-yl)porphyrin (MnTE-2-PyP4+) with
compounds 5 and 15. Hypsochromic shifts from 438 nm to 422 nm indicate coordinations of NO.
c(MnTE-2-PyP4+) = 0.5 mmol L–1, c(5 or 15) = 0.5 mmol L–1.
chemical entities with similar properties. Compounds 10, 16 and 17 are all molecules that
could mimic parts of aminoglycoside molecule and could still interact with nucleotides
in the modified A-site via nitrogen atoms in a manner similar to kanamycin or related
4,6-disubstituted 2-deoxystreptamine antibiotics. This could result in interference with
the protein synthesis and in turn affect the bacterial growth. In this respect, 10, 16 and 17
could even be considered as lead molecules for drug development in the treatment of re-
sistant bacteria that carry Arm methyltransferases as aminoglycoside resistance determi-
nants. Compounds 5, 7 and 15, on the other hand, could accommodate better into unmo-
dified A-site, thus having a more prominent effect on any bacterial strain that is either
susceptible to antibiotics, or carries any other resistance determinants, except the Arm
enzyme.
Manganese-porphyrin test
Dimethylsulfoxide solutions of compounds 5 and 15 showed instability and release
of gas bubbles a few hours after solubilization. Due to a high content of nitrogen and ox-
ygen in both compounds and findings of hydroxyurea as a nitric oxide donor, the corre-
sponding compounds were tested for NO formation using the manganese-porphyrin
test (5, 13, 24). Both 5 and 15 gave positive results (Figure 3), while all the other tested
compounds were negative in the manganese-porphyrin test. Effects on the metabolic sta-
tus of eukaryotic cells (25) and bacteriostatic activity (26) of NO have been demonstrated
earlier and these results are in accord with our findings. Mechanisms and kinetics of NO
production from 5 and 15 are out of scope of this paper and will be published elsewhere.
CONCLUSIONS
In this paper, the synthesis of new hydroxyurea cyclic and acyclic derivatives [1-
(N-metoxycarbamoyl)benzotriazole (3), 1-(N-ethoxycarbamoyl)benzotriazole (4), N-ben-
zyloxybiuret (6), 4-{[(benzyloxy)carbamoyl]amino}benzoic acid (7), 4-{[(hydroxy)car-
bamoyl]amino}benzoic acid (13) and N,N’,N’’-trihydroxybiuret (15)] and new synthetic
routes for these groups of compounds [1,1’-carbonylbisbenzotriazole (1), N-benzyloxy-
carbamoyl)benzotriazole (2), N,N’-bisbenzyloxyurea (9), N-hydroxybiuret (12) and
N-hydroxurea (14)] are disclosed. Metabolic activity test showed the cytotoxic potential
of twelve compounds (2–4, 7, 9 and 11–17). In addition, 1-(N-hydroxycarbamoyl)benzo-
triazole (5) stimulated metabolic activity, while compounds 1-(N-hydroxycarbamoyl)ben-
zotriazole (5) and N,N’,N’’-trihydroxybiuret (15) were identified as potential NO donors.
Six compounds showed antibacterial activity (5, 7, 10 and 15–17). Findings described in
this work could be used as guidelines for the preparation of new and modification of ex-
isting compounds, offering a model for tested biological effects in the drug discovery
process.
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